innoVactiv, a Canadian company dedicated to the development of science-based specialty ingredients, lauded the publication of its latest human clinical trial on InSea2 in the peer-reviewed journal Phytotherapy Research. 
 
The publication presents the results of a six-month, randomized, double-blinded, placebo-controlled clinical trial involving 65 dysglycemic subjects not using medication. Findings include significant reductions in glycated hemoglobin (HbA1c), fasting plasma glucose, postprandial glucose, and insulin resistance index (HOMA-IR) compared with placebo, as well as normalization of glycemic status in 18.2% of treated subjects versus 0% in placebo group. 
 
“We are thrilled about these new results, as they demonstrate the dramatic impact the use of InSea2  can have when taken on a daily basis. While all treated and placebo subjects followed the same strict diet and exercise regimen, researchers noticed a clear degradation of the glycemic condition in the placebo group, while two thirds of InSea2 subjects improved their glycemic status over the six months of the trial period,” said Jocelyn Bérubé, executive vice-president, science and regulatory affairs for innoVactiv. “While our previous clinical studies have shown an immediate benefit of a single InSea2  intake on glycemic stress and brain acuity, these new results now clearly demonstrate the benefits of a daily use of InSea2 on glycemic health when taken over a longer period of time.” 
 
Derived from brown seaweeds and rich in polyphenols, InSea2 is designed to help maintain healthy blood sugar and optimize the body's energy management after a meal.